ArticleAPL bioengineering2025
Heparan sulfate as a central modulator of growth factor dynamics in tissue regeneration.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heparan sulfate and glycomimetics: Advances in synthesis and biological applications for post-stroke neurorepair.Neuroprotection (Chichester, England) · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth factors (GFs) are potent regenerative proteins that modulate biological responses and stimulate tissue repair by activating cell signaling pathways to enhance proliferation, differentiation, and migration. However, the rapid degradation and diffusion characteristics of GFs necessitate the use of supraphysiological doses and/or frequent administrations to maintain therapeutic effects, which can result in reduced efficacy and an increased risk of adverse events. To address these challenges, novel GF delivery systems seek to preserve bioactivity and modulate GF release, ultimately promoting more effective tissue regeneration. Heparan sulfate (HS) is an essential regulator of GF activity, executing molecular recognition and information storage for controlling extracellular matrix remodeling and cellular behavior during tissue development. In this perspective, we summarize the diverse roles of HS in tissue repair, focusing on its interactions with GFs. These include protective functions, the tonic release of GFs, promoting the complexation of GFs with their cognate receptors, and enhancing the activation of intracellular signaling. Finally, we provide perspectives on using HS as a component of novel biomaterials and medical devices for improving tissue regeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.